Ahmedabad: With strong demand growth in the health care room and those who focus more on prevention after the outbreak of Covid-19 pandemic, pharmaceutical companies add more drugs and products to existing portfolios.
As a result, a substantial leap has occurred in the product approval provided to produce drugs in Gujarat.
For example: Food Administration and Gujarat Narcotics Control (FDCA) in September issued 5,494 licenses to make different allopathic drugs and products.
Except January and April, the number of product licenses given to pharmaceutical companies every month has floated above 5,000 signs this year, showing data compiled by FDCA-Gujarat.
“The number of product licenses issued every month is around 2,500 to 3,000 before the outbreak of Pandemic Covid-19.
The issuance of monthly product licenses has risen 1 to 1.5 times recently,” said Dr.
H G Koshia, Commissioner, FDCA-Gujarat.
The issuance of fresh product licenses began to increase after a pandemic and passed a monthly sign of 5,000 in 2021.
New product licenses of 5,601, 5,488 and 5,421 were issued by the FDCA State in April, May, July and August respectively.
That number reached 5,095 in February and 5,123 in March this year.
Low product approval at 3,981 and 3,725 in January and April, revealed FDCA data.
A total of 48,909 product licenses have been issued by the state FDCA this year.
“While health care and pharmacy have seen strong growth, people have begun to focus more on preventive care than curative after pandemics.
Therefore, the Pharma company added more prevention drugs for the list of existing products,” Koshia added.
Spurt in new product permits is also supported by a large rush of companies to produce products and therapies used in Covid-19 treatment.
It also includes making vitamins, nutrients, covid-19 drugs and their raw materials, said pharmaceutical industry players.
While the export of drugs has been strong since the pandemic struck, the growth of the domestic market has also risen strongly.
This has encouraged more companies to launch their products to meet increasing demand, add industrial players.
Products Pharma approval rises because the company expands a portfolio
